Perspectum, an Oxford, UK-based medical software company that provides non-invasive technology for identifying and monitoring multiple diseases, completed a $36M financing.
The round was co-led by the Blue Venture Fund and HealthQuest Capital, with participation from Oxford Science Innovation, Puhua Capital and the University of Oxford and other existing investors. In conjunction with the funding, Garheng Kong, MD, PhD, Managing Partner at HealthQuest will join the Perspectum Board.
The funding will drive the commercialization of LiverMultiScan® for clinical use, expand the CRO business as well as develop additional products for biliary disease, diabetes and cancer for both clinical and CRO applications.
Led by Dr Rajarshi Banerjee, Founder and Chief Executive Officer, Perspectum offers LiverMultiScan, an FDA-cleared technology solution that has proven accuracy and precision in assessment of liver tissue. This enables improved diagnostic pathways for liver disorders, such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). LiverMultiScan® is a diagnostic product that uses software to extract quantitative data from current MRI scans to aid with the detection of chronic liver disease.
Additionally, the company has an imaging-focused Contract Research Organization (CRO) solutions business that supports biopharmaceutical companies developing assets in liver and metabolic diseases.